Prelude Therapeutics Incorporated — Quarterly Financial Statistics (NASDAQ:PRLD) | MetaTrader

Open full chart

Financials

Overview 明細書 Statistics Dividends

Quarterly Annual

Cash from operating activities 27.3 M20.74 M34.23 M26.07 M19.11 M 100.17 M Cash from investing activities 10.73 M22.12 M62.19 M11.52 M40.09 M 135.92 M Cash from financing activities 41 K34 K160 K-37 K5 000 162 K Free cash flow 27.23 M20.69 M34.18 M26.05 M19.11 M 100.05 M

ニュース

L’action Prelude Therapeutics maintient sa note "Surperformance du marché" chez Citizens

Prelude Therapeutics stock gets reiterated Market Outperform rating at Citizens

Le titre de Prelude Therapeutics s’envole après l’approbation de la FDA pour un médicament anticancéreux

Prelude Therapeutics stock surges after FDA clears IND for cancer drug

Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)

Mizuho relève la note d’Incyte à Surperformance suite aux données prometteuses de l’ASH

Citizens réitère sa recommandation "Surperformance du marché" pour l’action Prelude Therapeutics

Prelude Therapeutics stock rating reiterated at Market Outperform by Citizens

Beat the Market the Zacks Way: Goldman Sachs, Micron, Prelude in Focus

La notation de l’action Prelude Therapeutics maintenue à "Surperformance"

Prelude Therapeutics stock rating reiterated at Market Outperform by Citizens

L’action d’Incyte atteint un sommet de 52 semaines à 108,81 USD